Hugel Aesthetics is building a direct sales organization in the US for Letybo (botulinum toxin type A), backed by a new K-TOX campaign designed to compete for market share against entrenched players. The move signals Hugel's commitment to move beyond wholesale distribution and establish brand presence among practitioners.
Letybo has gained traction in select US markets, but Hugel historically relied on third-party distribution. A direct sales force allows the company to control messaging, pricing, and rebate architecture—critical levers in a market where Allergan Aesthetics, Revance, and Evolus dominate through established relationships and loyalty programs (Alle, Aspire, Rewards).